Canada on Tuesday named a former deputy commissioner with the Royal Canadian Mounted Police as the country’s fentanyl czar, ...

After a mild Sunday in the 60s, colder highs return for the coming week with cold 30s and heavy rain chances in the Piedmont ...

The Chinese Communist Party, essentially a criminal organization, invests an entire supply chain into shipping opioid ...

The U.S. Postal Service began to allow inbound mail and packages from China and Hong Kong Posts on Wednesday, less than 24 ...

Kowloon Walled City was a lawless crime-ridden den rife that became the epicentre of opioid production in the heart of ...

Cosmetology school abruptly closes as Health and Style Institute leaves Triad students in limbo ...

Trump signed three executive orders late Saturday afternoon at his Mar-a-Lago resort in Florida, launching the salvoes. Layered on top of those already in place, the tariffs will ...

It's the first new pharmaceutical approach to treating pain in over 20 years, designed to eliminate risks of addiction and overdose associated with opioids.

For the first time in two decades, the Food and Drug Administration (FDA) has approved a new class of medication that provides an alternative to addictive opioids for patients looking to manage ...

Washington — Federal officials on Thursday approved a new type of pain drug designed to eliminate the risks of addiction and overdose associated with opioid medications like Vicodin and OxyContin.

( The Hill) – The U.S. Food and Drug Administration (FDA) approved Journavx (suzetrigine) oral tablets on Thursday as a first-in-class non-opioid analgesic to treat acute pain in adults.

The Food and Drug Administration on Tuesday approved Journavx, the first drug in a new class of non-opioid pain medications, for treating moderate to severe acute pain in adults. The oral tablet ...